Testing a New Drug for Advanced Lung Neuroendocrine Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment for advanced large-cell neuroendocrine cancer of the lung, a rare type of lung cancer. You may qualify if you've had one round of standard chemotherapy and your cancer has not improved with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have large-cell neuroendocrine cancer of the lung (confirmed by biopsy), where this type makes up at least half of your tumor
- Your cancer is advanced or has spread, and surgery or radiation cannot cure it
- You have received exactly one cycle of platinum-based chemotherapy (the standard first treatment), with or without immunotherapy
- You have not had any other systemic cancer treatments before, except for that one cycle of chemotherapy
- Your cancer can be measured on imaging scans (RECIST criteria)
- You do not have brain metastases causing symptoms, or if you do, they are stable and not requiring steroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (benmelstobart), a targeted therapy (anlotinib), and chemotherapy as the first treatment for advanced neuroendocrine cancers that started in the lung or gut. It aims to see if this combo works better than standard chemo alone.
This trial tests a new combination of two drugs, Obrixtamig and ZL-1310, in people with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Large Cell Neuroendocrine Carcinoma of the Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.